{"product_id":"afya-vrio-analysis","title":"Afya Limited (AFYA): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secret to Afya Limited (AFYA)'s market staying power with this razor-sharp VRIO Analysis. We distill the core of their operations to reveal precisely which assets are Valuable, Rare, Inimitable, and Organized to forge a truly sustainable competitive advantage. Read on to see the definitive summary of their strengths and why they are positioned to win.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAfya Limited (AFYA) - VRIO Analysis: Dominant Scale in Medical School Seats\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at Afya Limited’s core asset - the sheer volume of medical school seats - and wondering if it’s a durable moat. Honestly, it is. This scale is what anchors their financial projections and makes them tough to challenge in the Brazilian medical education space.\u003c\/p\u003e\n\n\u003cp\u003eHere is the quick math on why this scale matters right now.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Directly supports the projected full-year 2025 revenue guidance between R$3,670 million and R$3,770 million by securing the primary revenue base.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe undergraduate medicine segment is the engine here. With the company reaffirming its 2025 guidance to land between \u003cstrong\u003eR$3,670 million\u003c\/strong\u003e and \u003cstrong\u003eR$3,770 million\u003c\/strong\u003e, every seat is a high-margin, recurring revenue stream whose value is locked in by high student occupancy rates.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Possessing 3,753 approved medical seats makes it the largest in Brazil, which is rare in this highly regulated sector.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAs of November 7, 2025, Afya has \u003cstrong\u003e3,753\u003c\/strong\u003e total approved medical school seats. Finding another operator with this density in a market governed by the Ministry of Education (MEC) is nearly impossible in the near term. That’s defintely rare.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: High; regulatory hurdles and the time required to build new accredited schools make imitation slow and costly.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eYou can’t just buy land and start teaching medicine tomorrow. The process to get MEC accreditation for a new medical school takes years and significant capital outlay. What this estimate hides is the multi-year lag time for any competitor trying to organically match this footprint.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: High; the company uses a disciplined M\u0026amp;A pace, like the FUNIC acquisition in May 2025, to efficiently expand this footprint.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAfya doesn’t just sit on its scale; it grows it smartly. The May 2025 closing of Faculdade Única de Contagem (FUNIC) added \u003cstrong\u003e60\u003c\/strong\u003e seats for an aggregate price of \u003cstrong\u003eR$100 million\u003c\/strong\u003e. This shows they are organized to integrate and deploy capital effectively to maintain their lead.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained; the sheer scale creates barriers to entry for new, large-scale competitors.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis isn't a temporary edge; it’s structural. The combination of scale, regulatory know-how, and efficient M\u0026amp;A execution means this advantage should persist for the foreseeable future.\u003c\/p\u003e\n\n\u003cp\u003eHere is a quick summary of the VRIO assessment for this core resource:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eScore (1-4)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eHigh (Supports \u003cstrong\u003eR$3.67B-R$3.77B\u003c\/strong\u003e revenue guidance)\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eHigh (Largest operator with \u003cstrong\u003e3,753\u003c\/strong\u003e seats)\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (I)\u003c\/td\u003e\n\u003ctd\u003eHigh (Regulatory barriers are significant)\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eHigh (Disciplined M\u0026amp;A execution, e.g., FUNIC)\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained Competitive Advantage\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003eValue: Secures core revenue base.\u003c\/li\u003e\n\u003cli\u003eRarity: Largest scale in a tough market.\u003c\/li\u003e\n\u003cli\u003eImitability: Slow and expensive to copy.\u003c\/li\u003e\n\u003cli\u003eOrganization: Efficiently deployed via M\u0026amp;A.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday, incorporating the full impact of the Q3 performance and the reaffirmed 2025 guidance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAfya Limited (AFYA) - VRIO Analysis: Integrated Physician-Centric Digital Ecosystem\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Creates high customer lifetime value by serving students through graduation and into their professional practice via digital health solutions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; while digital tools exist, the seamless integration across education and practice for over 300 thousand users is unique in Brazil.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; the platform integration requires significant IT investment and deep domain knowledge to replicate effectively.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; management focuses on advancing AI-enabled enhancements across Afya Whitebook, iClinic, and ReceitaPro to reinforce this stickiness.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; competitors are trying to build similar end-to-end offerings, but Afya has a significant head start.\u003c\/p\u003e\n\u003cp\u003eThe value proposition is supported by the scale and financial performance of the integrated ecosystem.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUsers in Afya's Ecosystem\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e304k\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e9M 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUsers in Afya's Ecosystem\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e320,237\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Approved Medical Seats\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3,753\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of November 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical Students (Undergrad)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26k\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e9M 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Active Payers (Practice Solutions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e195,711\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital Services Net Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eR$65.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital Services YoY Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY Adjusted EBITDA Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e46.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e9M 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY Adjusted Net Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eR$2,874.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eManagement focus on AI-enabled enhancements is demonstrated by the integration of new features across core platforms.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eAfya Whitebook features \u003cstrong\u003eWB Assist\u003c\/strong\u003e, an AI assistant trained by Brazilian doctors.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eiClinic integrates \u003cstrong\u003eiClinic Assist\u003c\/strong\u003e, an AI feature within the electronic health record.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReceitaPro\u003c\/strong\u003e is introduced as a smart prescription solution.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe continued growth in user base and financial metrics reinforces the stickiness of the integrated offering.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eEcosystem Outreach grew from \u003cstrong\u003e268 thousand\u003c\/strong\u003e monthly active users in Q4 2023 to \u003cstrong\u003e320,237\u003c\/strong\u003e users in Q2 2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eFY23 Adjusted Net Revenue was \u003cstrong\u003eR$2,874.1 million\u003c\/strong\u003e, growing to R$3,304.3 million in FY24.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAfya Limited (AFYA) - VRIO Analysis: Disciplined, High-Yield M\u0026amp;A Capability\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Allows for rapid, accretive expansion into new geographic markets and seat capacity, as seen with the FUNIC addition.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe acquisition of FUNIC is expected to add \u003cstrong\u003e60 medical school seats\u003c\/strong\u003e for an aggregate purchase price of \u003cstrong\u003eR$100 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe acquisition of Unidom Participações S.A. on July 1, 2024, was for \u003cstrong\u003eR$620,762 thousand\u003c\/strong\u003e and added \u003cstrong\u003e300 medical school seats\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eWith recent additions, including Unidom, UNIMA expansion (80 seats), Guanambi expansion (40 seats), and Unigranrio reconsideration (10 seats), total approved medical school seats will reach \u003cstrong\u003e3,653\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company's FY2024 Net Revenue reached \u003cstrong\u003eR$3,304.3 million\u003c\/strong\u003e, a \u003cstrong\u003e14.9%\u003c\/strong\u003e increase year-over-year (YoY).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate; many companies attempt roll-ups, but Afya’s success in integrating schools while maintaining high margins is less common.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFY2024 Adjusted EBITDA Margin was \u003cstrong\u003e44.1%\u003c\/strong\u003e, an increase of \u003cstrong\u003e360 bps\u003c\/strong\u003e YoY.\u003c\/li\u003e\n\u003cli\u003eFY2023 Adjusted EBITDA Margin was \u003cstrong\u003e40.6%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAdjusted EBITDA excluding acquisitions grew \u003cstrong\u003e21.7%\u003c\/strong\u003e for FY2024, indicating strong organic performance alongside integration.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Moderate; the process is imitable, but the required due diligence and post-acquisition synergy realization are hard to copy.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe audit for the Unidom acquisition was noted as complex due to significant estimation uncertainties regarding contingent consideration liability and the valuation of intangible assets, suggesting high internal diligence requirements.\u003c\/li\u003e\n\u003cli\u003eFor the Unidom acquisition, Afya expects an EV\/EBITDA of \u003cstrong\u003e4.2x\u003c\/strong\u003e at maturity post synergies in 2027.\u003c\/li\u003e\n\u003cli\u003eFor the FUNIC acquisition, Afya expects an EV\/EBITDA of \u003cstrong\u003e3.3x\u003c\/strong\u003e at full maturity post synergies in 2030.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: High; the company maintains a strong balance sheet to fund these strategic, value-accretive purchases.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company's ability to fund large transactions while maintaining liquidity and managing debt is demonstrated by the following financial position as of December 31, 2024:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eFY2024 Amount (R$ million)\u003c\/td\u003e\n\u003ctd\u003eFY2023 Amount (R$ million)\u003c\/td\u003e\n\u003ctd\u003eChange\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e911.0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e553.0\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e64.7%\u003c\/strong\u003e Increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Debt (excluding IFRS 16)\u003c\/td\u003e\n\u003ctd\u003e1,814.9\u003c\/td\u003e\n\u003ctd\u003eIn line with prior year despite R$660.0M acquisition\u003c\/td\u003e\n\u003ctd\u003eManaged\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Cash Conversion Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e102.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e97.1% (FY23)\u003c\/td\u003e\n\u003ctd\u003eStrong Conversion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary; success depends on finding the right targets at the right price, which is not guaranteed long-term.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company declared a cash dividend of \u003cstrong\u003e20%\u003c\/strong\u003e of the 2024 consolidated net income of \u003cstrong\u003eR$648.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFY2024 Net Income was \u003cstrong\u003eR$648.9 million\u003c\/strong\u003e, a \u003cstrong\u003e60.1%\u003c\/strong\u003e increase YoY.\u003c\/li\u003e\n\u003cli\u003eThe company issued commercial notes totaling \u003cstrong\u003eR$1.5 billion\u003c\/strong\u003e in October 2025 to fund debt management and share repurchases, indicating active capital structure optimization.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAfya Limited (AFYA) - VRIO Analysis: High Operational Cash Conversion\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eTranslates strong earnings into readily available cash for funding growth, debt repayment, or shareholder returns, like the new share repurchase program. The program allows for the repurchase of up to \u003cstrong\u003e4,000,000\u003c\/strong\u003e of its outstanding Class A common shares, beginning from August 15, 2025 until December 31, 2026.\u003cstrong\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate; the Operating Cash Conversion ratio hit \u003cstrong\u003e101.5%\u003c\/strong\u003e for the nine-month period ending September 2025, which is excellent. This metric is based on Cash Flow from Operating Activities of \u003cstrong\u003eR$1,291.5 million\u003c\/strong\u003e for the nine-month period ended September 30, 2025.\u003cstrong\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eLow; this is a result of strong working capital management and high profitability, not a standalone asset. Supporting profitability metrics for the nine-month period ending September 30, 2025 include:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (9M 2025)\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eR$2,784.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e13.4%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eR$1,291.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e18.5%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e46.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e200 bps\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eR$593.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e19.9%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eHigh; this metric reflects the company’s focus on financial discipline, one of its three strategic pillars. The company demonstrated this discipline through capital structure strengthening actions in October 2025.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and Cash Equivalents as of September 30, 2025: \u003cstrong\u003eR$996.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Debt reduction (excluding IFRS 16, vs. Dec 31, 2024): Decrease of \u003cstrong\u003eR$472.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRepurchase of Series A Preferred Shares: \u003cstrong\u003e150,000\u003c\/strong\u003e shares for \u003cstrong\u003eR$831.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRepayment of first issuance of debentures: \u003cstrong\u003eR$500 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained; as long as profitability remains high and working capital is managed well, this will persist. The company's ability to generate cash in excess of reported earnings (ratio over 100%) supports its strategic flexibility.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAfya Limited (AFYA) - VRIO Analysis: Strong Brand Equity in Medical Education\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Drives high student demand, allowing for premium pricing and near-full occupancy in its medical programs.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe high demand is evidenced by the scale of its student base, which supports significant revenue generation.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (FY 2024)\u003c\/th\u003e\n\u003cth\u003eValue (9M 2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenue (R$ '000)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3,304,300\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2,784,300\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUndergrad Medical School Students (End of Period)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e24,255\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e26,000\u003c\/strong\u003e (Implied from 9M 2025 data context)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContinuing Education Students (End of Period)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50,521\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproximate Revenue Mix from Undergraduate Medical Education\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~75%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe core medical education segment commands pricing power, contributing to an Adjusted EBITDA Margin of \u003cstrong\u003e44.1%\u003c\/strong\u003e for FY 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: High; being the 'leading medical education group' implies significant trust built over years of operation since its precursor’s founding in 1999.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe longevity of the brand's precursor establishes a rare historical foundation in the market.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePrecursor founding year: \u003cstrong\u003e1999\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Users in Afya's Ecosystem (FY 2024): Over \u003cstrong\u003e313,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Users in Afya's Ecosystem (9M 2025): Over \u003cstrong\u003e304,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: High; brand trust in professional education takes decades to build and cannot be bought quickly.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe intangible asset of trust is difficult to replicate, contrasting with the company's ability to acquire physical assets like medical seats.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition of FUNIC (60 seats) Deal Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eR$ 100 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Additional Cost Per Seat (if approved)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eR$ 1 million\u003c\/strong\u003e per seat (up to 60 seats)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003eWhile seats can be acquired, the associated brand premium and student loyalty are not directly transferable through simple transactions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: High; the brand is reinforced by consistent high-quality educational outcomes and strong performance metrics.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organization effectively leverages its brand equity through strong financial performance and ecosystem integration.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFY 2024 Adjusted EBITDA Margin: \u003cstrong\u003e44.1%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e9M 2025 Adjusted EBITDA Margin: \u003cstrong\u003e46.4%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFY 2024 Operating Cash Conversion Ratio: \u003cstrong\u003e102.2%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e9M 2025 Operating Cash Conversion Ratio: \u003cstrong\u003e101.5%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained; this intangible asset is a major moat against new entrants.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe combination of historical brand trust and current operational excellence creates a durable competitive barrier.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAfya Limited (AFYA) - VRIO Analysis: Near-Perfect Medical School Occupancy Rate\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Ensures predictable, recurring tuition revenue streams and maximizes the return on its high-fixed-cost physical assets (schools).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; maintaining a near-100% occupancy rate across its medical schools is a significant operational feat in Brazil.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; it requires superior marketing, reputation, and admissions processes that competitors struggle to match.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this is a direct output of the strong brand and the desirability of its educational product.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; this operational excellence is deeply embedded in their student acquisition process.\u003c\/p\u003e\n\u003cp\u003eThe operational excellence in student acquisition is quantified by recent capacity and performance metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOccupancy rate for medical school seats remained steady at approximately \u003cstrong\u003e100%\u003c\/strong\u003e for the three months ended December 31, 2024, and for the first quarter of 2025 (three months ended March 31, 2025).\u003c\/li\u003e\n\u003cli\u003eThe company cited a medical campus in Salvador that reached nearly full occupancy within \u003cstrong\u003etwo\u003c\/strong\u003e intake processes under Afya, up from below \u003cstrong\u003e60%\u003c\/strong\u003e when acquired.\u003c\/li\u003e\n\u003cli\u003eThe acquisition of FUNIC added \u003cstrong\u003e60\u003c\/strong\u003e new medical seats.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eKey capacity and financial figures related to the medical school segment:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Approved Medical School Seats\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3,653\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of the second quarter of 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Approved Medical School Seats\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3,163\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical School Regulatory Capacity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3,593\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIn 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Reported Net Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eR$919.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThree months period ended June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eR$936.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFirst quarter of 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Tuition Fees (ex-Acquisitions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eR$2,332,745 thousand\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTwelve months period ended December 31, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUndergraduate (Medical School Students - End of Period)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25,733\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSix months period ended June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe high occupancy directly supports the financial performance, as seen in the revenue growth:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Revenue for the first quarter of 2025 increased \u003cstrong\u003e16.4%\u003c\/strong\u003e year-over-year to \u003cstrong\u003eR$936.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Income for the first quarter of 2025 increased \u003cstrong\u003e23.4%\u003c\/strong\u003e year-on-year, reaching \u003cstrong\u003eR$257.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFor the three months ending June 30, 2024, revenue surged to \u003cstrong\u003eR$809.89 million\u003c\/strong\u003e, a \u003cstrong\u003e13.7%\u003c\/strong\u003e increase from the prior year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAfya Limited (AFYA) - VRIO Analysis: Controlling Dual-Class Share Structure\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis focuses on the governance structure where Bertelsmann SE \u0026amp; Co. KGaA maintains significant voting control.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe dual-class share structure provides management with stability, insulating it from short-term market pressures or activist investors, enabling a focus on long-term strategic execution, such as the ecosystem build-out.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eShareholder Group\u003c\/td\u003e\n\u003ctd\u003eVoting Power (as of 11\/12\/2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBertelsmann SE \u0026amp; Co. KGaA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e75.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEsteves Family\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe structure is present in many Brazilian companies, but the specific level of control held by Bertelsmann SE \u0026amp; Co. KGaA is a distinct governance feature.\u003c\/p\u003e\n\u003cp\u003eHistorical voting power context:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBertelsmann held \u003cstrong\u003e46%\u003c\/strong\u003e of voting rights upon initial significant investment in August 2021.\u003c\/li\u003e\n\u003cli\u003eVoting power increased to \u003cstrong\u003e57.5%\u003c\/strong\u003e following the May 2022 transaction.\u003c\/li\u003e\n\u003cli\u003eOwnership disclosed as \u003cstrong\u003e53.07%\u003c\/strong\u003e of the company as of March 29, 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eChanging this structure is considered high in imitability due to the requirement for significant shareholder consensus, which is unlikely given the current controlling setup.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe structure allows management to execute long-term strategies, such as the ecosystem expansion, without distraction from short-term shareholder demands.\u003c\/p\u003e\n\u003cp\u003eEvidence of long-term strategy execution and scale:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEcosystem Outreach users: Over \u003cstrong\u003e313 thousand\u003c\/strong\u003e users as of December 31, 2024.\u003c\/li\u003e\n\u003cli\u003eEcosystem users: Approximately \u003cstrong\u003e320 thousand\u003c\/strong\u003e users in 1H24.\u003c\/li\u003e\n\u003cli\u003eFull Year 2024 Net Revenue: \u003cstrong\u003eR$3,304.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFull Year 2024 Adjusted EBITDA: \u003cstrong\u003eR$1,455.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained; this governance feature provides a structural advantage in the consistent execution of multi-year strategic plans.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAfya Limited (AFYA) - VRIO Analysis: Sustained High Adjusted EBITDA Margin\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDemonstrates superior profitability and cost control, with the 9M 2025 margin reaching \u003cstrong\u003e46.4%\u003c\/strong\u003e, allowing for reinvestment. The 9M 2025 Adjusted EBITDA was \u003cstrong\u003eR$1,291.7 million\u003c\/strong\u003e on Revenue of \u003cstrong\u003eR$2,784.3 million\u003c\/strong\u003e. The Adjusted EBITDA Margin for the first half of 2025 (1H25) was \u003cstrong\u003e48.1%\u003c\/strong\u003e, showing a high benchmark, while the third quarter (3Q25) margin was \u003cstrong\u003e43.0%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e9M 2025 Value\u003c\/th\u003e\n\u003cth\u003eYoY Change\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e46.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+200 bps\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eR$1,291.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+18.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eR$2,784.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+13.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Margin (Excl. Acquisitions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e46.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eR$593.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+19.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; while high, the margin is a result of scale and segment mix (high-margin Continuing Education\/Digital). The 9M 2025 margin of \u003cstrong\u003e46.4%\u003c\/strong\u003e compares to \u003cstrong\u003e48.1%\u003c\/strong\u003e for 1H 2025 and \u003cstrong\u003e43.0%\u003c\/strong\u003e for 3Q 2025, indicating variability but sustained high performance relative to potential benchmarks.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; competitors can improve margins, but matching Afya’s scale and segment mix is tough. The ecosystem supports \u003cstrong\u003e~304 thousand\u003c\/strong\u003e users as of 9M 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; the margin expansion (up \u003cstrong\u003e200 bps\u003c\/strong\u003e YoY for 9M 2025) shows effective cost management is a core focus. This was driven by specific operational improvements:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eHigher gross margin in the Undergraduate and Continuing Education segments.\u003c\/li\u003e\n\u003cli\u003eRestructuring initiatives within Continuing Education and Medical Practice Solutions.\u003c\/li\u003e\n\u003cli\u003eImproved efficiency in Selling, General, and administrative expenses.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe 9M 2025 Adjusted EBITDA excluding acquisitions grew \u003cstrong\u003e13.8%\u003c\/strong\u003e YoY, reaching \u003cstrong\u003eR$1,239.9 million\u003c\/strong\u003e with a margin of \u003cstrong\u003e46.0%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary; while strong now, margin pressure from competition is always a risk in education. The 9M 2025 Basic EPS growth was \u003cstrong\u003e19.7%\u003c\/strong\u003e YoY, demonstrating current financial strength.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAfya Limited (AFYA) - VRIO Analysis: Proprietary Digital Tools for Clinical Practice\n\u003c\/h2\u003e\n\u003cp\u003eProprietary Digital Tools for Clinical Practice\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Component\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eSupporting Data\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePresent\u003c\/td\u003e\n\u003ctd\u003eEvidence-based decision support enhances physician productivity; creates a captive post-graduate audience.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eTools exist, but deep integration into the professional workflow is the differentiating factor.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eDevelopment and validation require specialized medical and technology expertise.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eActively used to strengthen the entire physician journey, from student to practicing doctor.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eTechnology evolution pace necessitates continuous innovation to maintain superiority over rivals.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e~304 thousand users\u003c\/strong\u003e in Afya's ecosystem as of September 2025, utilizing digital products supported by the data platform.\u003c\/li\u003e\n\u003cli\u003eThe Medical Practice Solutions segment includes Afya Whitebook and Afya iClinic revenues.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinancial Context and Cash Position\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThe 13-week cash flow projection incorporates the Q3 2025 cash position of \u003cstrong\u003eR$ 996.8 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eThis cash position represented a \u003cstrong\u003e9.4%\u003c\/strong\u003e increase from December 31, 2024.\u003c\/li\u003e\n\u003cli\u003eOperating Cash Conversion ratio for the nine months ended September 30, 2025, was \u003cstrong\u003e101.5%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Debt, excluding the effect of IFRS 16, was \u003cstrong\u003eR$ 1,342.2 million\u003c\/strong\u003e as of September 30, 2025, a decrease of \u003cstrong\u003eR$ 472.7 million\u003c\/strong\u003e compared to December 31, 2024.\u003c\/li\u003e\n\u003cli\u003eIn October 2025, the company issued commercial notes totaling \u003cstrong\u003eR$1.5 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric (9M 2025)\u003c\/td\u003e\n\u003ctd\u003eAmount (R$)\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eR$ 2,784.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncreased \u003cstrong\u003e13.4%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eR$ 1,291.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncreased \u003cstrong\u003e18.5%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e46.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncreased \u003cstrong\u003e200 bps\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eR$ 593.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncreased \u003cstrong\u003e19.9%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516106137749,"sku":"afya-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/afya-vrio-analysis.png?v=1740142582","url":"https:\/\/dcf-model.com\/fr\/products\/afya-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}